Bio-Techne Corporation (NASDAQ:TECH) Q1 2025 Earnings Conference Call October 30, 2024 9:00 AM ET
Company Participants
David Clair – Vice President-Investor Relations
Kim Kelderman – President and Chief Executive Officer
Jim Hippel – Chief Financial Officer
Conference Call Participants
Puneet Souda – Leerink Partners
Jacob Johnson – Stephens
Dan Leonard – UBS
Thomas DeBourcy – Nephron Research
Justin Bowers – Deutsche Bank
Tom Peterson – Baird
Matt Larew – William Blair
Sung Ji Nam – Scotiabank
Operator
Good morning, and welcome to the Bio-Techne Earnings Conference Call for the First Quarter of Fiscal Year 2025. At this time, all participants have been placed in listen-only mode and the call will be open for questions following management’s prepared remarks. During our Q&A session, please limit yourself to one question and one follow-up.
I would now like to turn the call over to David Clair, Bio-Techne’s Vice President, Investor Relations.
David Clair
Good morning, and thank you for joining us. On the call with me this morning are Kim Kelderman, President and Chief Executive Officer; and Jim Hippel, Chief Financial Officer of Bio-Techne.
Before we begin, let me briefly cover our safe harbor statement. Some of the comments made during this conference call may be considered forward-looking statements, including beliefs and expectations about the company’s future results.
The company’s 10-K for fiscal year 2024 identifies certain factors that could cause the company’s actual results to differ materially from those projected in the forward-looking statements made during this call. The company does not undertake to update any forward-looking statements because of any new information or future events or developments. The 10-K, as well as the company’s other SEC filings, are available on the company’s website within its Investor Relations section.
During the call, non-GAAP financial measures may be used to provide information pertinent to
Be the first to comment